Abstract: P-glycoprotein, encoded by ABCB1, is an ATP-dependent drug efflux pump which exports substances outside the cell. Some studies described connections between C3435T polymorphism T allele and lower P-glycoprotein expression; therefore, homozygous T/T could show higher plasma levels. Our aim was to evaluate the effect of C3435T on pharmacokinetics of 4 antipsychotics (olanzapine, quetiapine, risperidone and aripiprazole) and 4 antidepressants (trazodone, sertraline, agomelatine and citalopram). The study included 473 healthy volunteers receiving a single oral dose of one of these drugs, genotyped by real-time PCR. Multivariate analysis was performed to adjust the effect of sex and genotype of the main cytochrome P450 enzymes. C3435T polymorphism had an effect on olanzapine pharmacokinetics, as T/T individuals showed lower clearance and volume of distribution. T/T individuals showed lower T 1/2 of 9-OH-risperidone, but this difference disappeared after multivariate correction. T/T homozygous individuals showed lower dehydro-aripiprazole and trazodone area under the concentration-time curve, along with lower half-life and higher clearance of trazodone. C/T genotype was associated to higher citalopram maximum concentration. C3435T had no effect on quetiapine, sertraline or agomelatine pharmacokinetics. C3435T can affect the elimination of some drugs in different ways. Regarding risperidone, trazodone and dehydro-aripiprazole, we observed enhanced elimination while it was reduced in olanzapine and citalopram. However, in quetiapine, aripiprazole, sertraline and agomelatine, no changes were detected. These results suggest that P-glycoprotein polymorphisms could affect CNS drugs disposition, but the genetic factor that alters its activity is still unknown. This fact leads to consider the analysis of ABCB1 haplotypes instead of individual variants.
P-glycoprotein (P-gp) is an ATP-dependent efflux pump that transports a wide range of xenobiotic compounds, pumping them out of the tissue in which it is expressed [1] . It is coded by ABCB1 (ATP-binding cassette subfamily B member 1), also known as MDR1 (multidrug-resistance gene 1) [2, 3] . P-gp is expressed in specialized epithelial cells of secretory/excretory organs (liver, kidneys, small intestine) and in endothelial cells of capillary blood vessels at blood-tissue barriers, such as the blood-brain barrier (BBB) or the placenta [4] . Due to the particular localization of this transporter, it is believed that P-gp can have an implication in drug absorption, distribution, metabolism and excretion (ADME) [5, 6] . Therefore, P-gp expression level and functional integrity may influence the pharmacokinetics of drugs which are substrates of this transporter [7] .
Genetic polymorphisms of ABCB1 can lead to variations in P-gp expression or function, thus, contributing to inter-individual variability in drug absorption and disposition [8] [9] [10] . A large number of single nucleotide polymorphisms (SNPs) have been identified in ABCB1 [11, 12] . The most studied polymorphism is the synonymous SNP rs1045642, also known as C3435T, which is a transition in exon 26 of the ABCB1 gene that could influence P-gp activity [11] .
Some studies have reported a lower P-gp expression in T allele carriers [13] [14] [15] [16] . For that reason, if T allele is associated with a reduced functionality of P-gp, it is expected that carriers of this allele show higher levels of P-gp substrate drugs as a consequence of a reduced elimination. However, other studies could not establish any association [17, 18] . To date, it remains unclear how C3435T can influence the protein expression and the only confirmed fact is that this SNP alters the substrate specificity [19] . Kimchi-Safarty et al. analysed the effect of C3435T by expressing wild-type and polymorphic Pgp in HeLa cells. No difference on either mRNA or protein levels was found between the distinct types of cell lines, but altered conformations were detected, suggesting that C3435T polymorphism could change the structure of substrate and inhibitor interaction sites [19] .
The presence of P-gp in the BBB explains its involvement in the delivery of drugs targeting the central nervous system (CNS). Second-generation antipsychotics and antidepressants are known to be effective, but a high number of patients do not reach a good treatment response or suffer adverse events (AEs) [20] [21] [22] . As most of the CNS-target drugs are P-gp substrates, the expression of this transporter could be a key limiting factor in the treatment of psychiatric diseases. Thus, genetic variations in P-gp might affect the response to treatment, remission and side effects risk [23] . Up to the present, although some research studies of major depressive disorder (MDD) and psychosis have shown an influence of ABCB1 polymorphisms in treatment outcome [24] [25] [26] [27] , in most cases, these results could not be replicated [28] [29] [30] [31] [32] .
Our purpose was to study the role of ABCB1 C3435T polymorphism on the pharmacokinetics of 4 antidepressants (trazodone, sertraline, agomelatine and citalopram) and 4 antipsychotics (aripiprazole, quetiapine, olanzapine and risperidone) in healthy volunteers to elucidate whether it is a relevant pharmacogenetic factor affecting the disposition of antidepressant and antipsychotic drugs.
Materials and Methods
Study population. Our study population comprised 473 healthy volunteers participating in 16 bioequivalence clinical trials performed at the Clinical Trials Unit of Hospital Universitario de la Princesa (Madrid, Spain) between 2003 and 2017. A variable number of volunteers of different clinical trials were included in this study: olanzapine (2 trials, n = 61), quetiapine (2 trials, n = 79), risperidone (2 trials, n = 70), aripiprazole (6 trials, n = 148), trazodone (1 trial, n = 36), sertraline (1 trial, n = 34), agomelatine (1 trial, n = 28) and citalopram (1 trial, n = 17).
The protocols complied with current Spanish Legislation on clinical research in humans and were approved by the Research Ethics Committee, duly authorized by the Spanish Drugs Agency and under the guidelines of Good Clinical Practice. All individuals gave their written informed consent for both clinical trial and pharmacogenetic studies.
The inclusion criteria were as follows: non-smoking male and female volunteers, age 18 to 55 years, body mass index within the 18.5-30.0 range, free from any organic or psychiatric conditions, with normal vital signs, electrocardiogram, medical records and physical examination. Individuals were free to withdraw from the study at any time.
Study design and procedures. Each study was a bioequivalence clinical trial where a test formulation was compared to a reference formulation, after a single oral dose administration under fasting conditions. The corresponding dosage of each drug was 5 mg olanzapine, 25 mg quetiapine, 1 mg risperidone, 10 mg aripiprazole, 100 mg trazodone, 100 mg sertraline, 25 mg agomelatine and 30 mg citalopram.
All clinical trials were randomized, open-label, cross-over, two-period, two-sequence, single-centre studies with blind determination of the plasma concentrations of the drug, except agomelatine, which was a replicated study (four-period, four-sequence). Individuals fasted from 10 hr before to 5 hr after drug administration. A variable number of blood samples for the pharmacokinetics assessment were obtained based on the pharmacokinetic characteristics of each compound: 17 samples for olanzapine (from 0 to 96 hr); 15 samples for quetiapine: (0-24 hr); 17 samples for risperidone (0-96 hr); 20 samples for aripiprazole (0-72 hr); 22 samples for trazodone (0-48 hr); 16 samples for sertraline (0-92 hr); 20 samples for agomelatine (0-24 hr) and 16 samples for citalopram (0-120 hr).
Samples were centrifuged for 10 min. at 3500 rpm (1900 9 g). All the plasma samples of olanzapine, quetiapine, risperidone, sertraline and citalopram were stored at À30°C; samples of aripiprazole, trazodone and agomelatine were stored at À20°C until its shipment to the external analytical laboratory.
Plasma concentrations of the studied drugs were measured in an accredited external laboratory by reverse phase high-performance liquid chromatography coupled to tandem mass spectrometry (HPLC-MS/MS) methods [33] [34] [35] [36] [37] [38] , validated according to FDA and EMA guidelines. Moreover, aripiprazole and dehydro-aripiprazole plasma concentrations were determined in our laboratory by a validated HPLC-MS/MS method [39] .
Pharmacokinetic analysis. Pharmacokinetic parameters were calculated using non-compartmental methods. In the case of risperidone and aripiprazole, we also analysed the pharmacokinetics of their major metabolites (9-OH-risperidone and dehydro-aripiprazole). The analysis was carried out using WinNonlin Professional (version 2.0, Pharsight Corporation, Palo Alto, CA, USA).
The maximum plasma concentration (C max ) and time to reach the maximum plasma concentration (T max ) were obtained directly from raw data. The area under the curve (AUC) from administration to the last measured concentration (AUC t ) was calculated by linear trapezoidal integration. The total AUC from administration to infinity (AUC ∞ ) was calculated as the sum of AUC t and the residual area (C t divided by k e , with C t as the last measured concentration and k e as the apparent terminal elimination rate, which was estimated by log-linear regression from the terminal portion of the log-transformed concentration-time plots). Half-life (T 1/2 ) was calculated by dividing 0.693 by k e . Values of AUC correspond to AUC t, except for aripiprazole and dehydro-aripiprazole, where AUC corresponds to AUC 0-72 h and trazodone, sertraline, citalopram and agomelatine where AUC corresponds to AUC ∞ .
The total drug clearance adjusted for bioavailability (Cl/F) was calculated by dividing the dose by the AUC ∞ and adjusting for weight. Volume of distribution adjusted for bioavailability (V d /F) was calculated as Cl/F divided by k e . AUC, and C max was adjusted for dose and weight (AUC/dW and C max /dW, divided by the dose-by-weight ratio) and logarithmically transformed for statistical analysis.
We analysed both formulations (test and reference) and considered the mean for each individual as they showed bioequivalence in all the studied drugs except agomelatine. In this case, test formulation was not bioequivalent; therefore, we considered the mean of the two reference administrations.
Genotyping. DNA was extracted from 1 mL of peripheral blood samples using MagNA Pure LC DNA Isolation Kit in an automatic DNA extractor (MagNa Pureâ System; Roche Applied Science, Indianapolis, IN, USA) and quantified spectrophotometrically in a NanoDropâ ND-1000 Spectrophotometer (NanoDrop Technologies Inc, Wilmington, DE, USA) where the purity of the samples was measured by A 260 / 280 absorbance ratio.
The polymorphisms of the individuals participating in risperidone, quetiapine and olanzapine studies were analysed using PharmaChip (Progenika Biopharma S.A., Vizcaya, Spain) [40] , a commercial tool which suitability in pharmacogenetic genotyping has been described previously [41, 42] . It includes genetic variants previously related to or potentially involved in the outcome of therapy with several drugs.
In the rest of the studies, C3435T polymorphism was genotyped with the StepOnePlus TM instrument (Applied Biosystems StepOne TM Real-Time PCR System, Foster City, CA, USA) using the commercial TaqMan assay C___7586657_20. Amplification conditions were an initial denaturation step of 95°C for 10 min.; 50 cycles of 95°C for 15 sec. and 60°C for 90 sec.; and a post-PCR read holding stage of 60°C for 30 sec. Moreover, we considered the genotype or phenotype data of several cytochrome P450 enzymes involved in the metabolism of these drugs and previously known to have an impact on the pharmacokinetics of the studied drugs. We investigated the effect of CYP3A5*3 (rs776746) in olanzapine [33] , CYP1A2*1C (rs2069514) and *1F (rs762551) in quetiapine [34] and agomelatine, CYP2D6 phenotype in risperidone [35] and aripiprazole [43] , CYP3A4 *22 (rs35599367) and CYP3A5*3 in tradozone [37] , CYP2C19 phenotype and CYP2B6 G516T (rs3745274) in sertraline [38] and CYP2C19 phenotype in citalopram.
In case of CYP2C19, phenotype was inferred from CYP2C19*2 (rs4244285), *3 (rs4986893) and *17 (rs12248560) allele determination. For CYP2D6, phenotype was inferred from CYP2D6*3 (rs35742686), *4 (rs3892097), *5 (deletion), *6 (rs5030655) and *9 (rs5030656) allele determination and Copy Number Variation (CNV) analysis. Phenotypes were classified according to CPIC allele definition [44] and allele functionality tables, as the one described by Gaedigk et al. for the activity of CYP2D6 alleles [45] .
For this purpose, CYP2D6*3, *4 and *5 and CYP2C19*2, *3 and *17 polymorphisms were studied by real-time PCR using LightCylerâ 2.0 instrument (RocheDiagnostics, Mannheim, Germany). A set of primers and probes were designed by TIB MOLBIOL (Berlin, Germany). CYP3A4*22, CYP3A5*3, CYP2B6 G516T, CYP1A2*1C and *1F, CYP2D6*6 and *9 polymorphisms were genotyped using a StepOnePlus TM PCR instrument (Applied Biosystems, Foster City, CA, USA). To determine the CNV in CYP2D6, we used a TaqMan Copy Number Assay (Applied Biosystems, Foster City, CA, USA), as described previously [43] .
Statistical analysis. Statistical analyses were performed with the SPSS 22.0 software (SPSS Inc., Chicago, IL, USA). We considered p values lower or equal to 0.05 to be statistically significant. The HardyWeinberg equilibrium was estimated for the analysed variant.
Deviations from the equilibrium were detected by comparing the observed and expected frequencies using a Fisher's exact test based on the De Finetti program (available at [46] ). Differences in the genotype frequencies according to sex were determined using a corrected Pearson chi-square test. Differences in pharmacokinetic parameters between individuals with different genotypes were statistically analysed by a parametric univariate analysis (t-test or ANOVA). A multiple regression analysis was performed to evaluate the effect of other possible factors such as sex and cytochrome P450 enzymes in the pharmacokinetic parameters evaluated.
To simplify the analysis, CYP2C19 genotypes were classified according to the number of functional alleles into poor metabolizers (PM) (*2/*2), intermediate metabolizers (IM) (*1/*2 and *2/*17), normal metabolizers (NM) (*1/*1) and ultra-rapid metabolizers (UM) (*1/*17 and *17/*17). Likewise, CYP2D6 genotypes were classified into 4 phenotypes (PM, IM, NM and UM) according to the method of Gaedigk et al. which is based on the functionality of alleles [45] .
Results

Genotype frequencies.
A total of 473 healthy volunteers were included in this study (260 men and 213 women). In all cases, the C3435T polymorphism was in Hardy-Weinberg equilibrium. There were no differences between men and women in the distribution of genotypes (table 1), but in citalopram population where only women carried T/T genotype.
Pharmacokinetic analysis.
The associations found between some pharmacokinetic parameters of antipsychotics and antidepressants and C3435T polymorphism are shown in tables 2 and 3, respectively. Additionally, the results of multivariate analysis are shown in table 4 . Figure 1 shows the comparison of Cl/F of the studied drugs according to individuals' C3435T genotypes. The most important findings are described below.
Antipsychotics. We failed to find associations between olanzapine pharmacokinetics and ABCB1 C3435T genotype in the univariate analysis. However, we observed a slightly higher AUC and lower Cl/F ( fig. 1 ) along with lower V d /F in T/T individuals. These differences in Cl/F and V d /F were confirmed in the multivariate analysis (table 4) after correction for sex and CYP3A5*3 genotype.
No differences were found between ABCB1 C3435T genotype and pharmacokinetic parameters of quetiapine in neither univariate nor multivariate analyses. The influence of sex and CYP1A2*1C genotype on pharmacokinetic parameters was confirmed (table 4) .
Although it did not reach statistical significance, pharmacokinetic parameters of risperidone were associated with ABCB1 C3435T genotype, but in the opposite manner than expected as T/T individuals showed lower AUC (p = 0.079), C max (p = 0.058) and T 1/2 (p = 0.096) and higher Cl/F (p = 0.079) ( fig. 1 ). Grouping the individuals into carriers and non-carriers of T allele, we observed that these differences were statistically significant (table 2) . Moreover, T/T individuals showed a significantly lower T 1/2 of 9-OH-risperidone (p = 0.05). Besides, after correction by CYP2D6 phenotype and sex in the multivariate analysis, some of these differences continued to be statistically significant (table 4) . Table 2 . ABCB1 C3435T effect on pharmacokinetic parameters of antipsychotics. Values are presented as mean (S.D.). Table 4 .
Results from the multivariate analysis considering ABCB1 C3435T with the principal CYP450 metabolizing enzymes affecting pharmacokinetic parameters of the antipsychotics and antidepressants analysed. Variable AUC (ngÁh/mL) 
We observed a trend in T/T individuals to show higher AUC, C max and T 1/2 of aripiprazole (p = 0.473, p = 0.855 and p = 0.081, respectively) (table 2), but this differences did not reach the statistical significance in multivariate analysis after adjusting for CYP2D6 and sex (table 4) . However, we found that individuals with T/T genotype showed lower dehydro-aripiprazole AUC (p = 0.051) and C max (p = 0.077), which was confirmed in the multivariate correction (table 4) .
Antidepressants. Differing to other drugs, T/T individuals showed lower AUC, C max and T 1/2 of trazodone although it did not reach statistical significance (p = 0.052, p = 0.139 and p = 0.107, respectively) (table 3) . Moreover, T/T individuals showed higher Cl/F (p = 0.054) ( fig. 1) .
After correction for CYP3A4 and CYP3A5 genotype in the multivariate analysis, the differences in AUC and Cl/F remained significant (table 4) .
We observed a trend in T/T individuals to show lower Cl/F of sertraline ( fig. 1 ). However, we did not find any association between sertraline pharmacokinetics and C3435T in neither univariate (table 3) nor multivariate analyses (table 4) . However, we observed an influence of CYP2C19 UM phenotype and CYP2B6 T/T genotype on sertraline AUC and T 1/2 , respectively.
T/T individuals showed lower Cl/F of agomelatine ( fig. 1 ), but these differences did not reach statistical significance in univariate or multivariate analyses (tables 3 and 4).
In the analysis of citalopram, we observed a tendency to show higher AUC, C max and T 1/2 in T allele carriers (p = 0.450, 0.054 and p = 0.857, respectively) (table 3). In fact, in multivariate analysis with CYP2C19 phenotype, there was an association between C max and ABCB1 C/T genotype (table 4).
Discussion
Genetic variability on pharmacogenes can influence drug metabolism, transport and elimination. Thus, the way patients respond to pharmacotherapy can be altered, in terms of efficacy or experiencing adverse reactions. Further evidence is needed to support pharmacogenetic testing when initiating antipsychotic or antidepressant therapy. In this regard, ABCB1 C3435T variant has been widely studied finding discordant results. Even though it has been hypothesized that a rare codon marked by the polymorphism alters the structure of substrate and inhibitor interaction sites in vitro [19] , the real implications are not clear as the associations found with the pharmacokinetic parameters of several drugs are not consistent or easily reproducible.
Genotype influence on pharmacokinetics of antipsychotics.
Olanzapine. Due to in vitro studies, the affinity of olanzapine to P-gp had been questioned [48, 49] but in vivo studies demonstrated its strong dependence on the transporter [50] . In a clinical trial of 10 healthy male volunteers, Markowitz et al. found a significant increase in olanzapine AUC in T/T homozygous of C3435T polymorphism [51] . Further evidence of C3435T influence on olanzapine was provided by Lin et al. whose study revealed a better treatment response in patients carrying T/T genotype [27] . Consistently, in our study after correction for the influence of CYP3A5*3 allele [33] , we found significantly lower Cl/F and V d /F in T/T individuals which means these individuals could accumulate more parent drug and have higher AUC. Nevertheless, later studies failed to reproduce these results in a larger sample size [52, 53] . Ghotbi et al. analysed the effect of ABCB1 haplotype on daily-corrected plasma concentrations of olanzapine in 121 patients, and they were unable to find any significant effect [52] . Another study in 87 female patients displayed a similar result with C3435T polymorphism [53] . Differences in the study design and the influence of other genotypes can explain why studies with larger sample size could not find significant differences. Nonetheless, further research is needed on this issue.
Quetiapine. Similar to olanzapine, in vitro assays attempted to verify the involvement of P-gp in the transport of quetiapine and did not reach a consistent conclusion. Some studies found that quetiapine has high affinity for P-gp [48, 49] . However, Grimm et al. considered quetiapine as a non-substrate of P-gp [54] . Moreover, another study observed that quetiapine transport across the blood-placenta barrier was not affected by P-gp inhibition [55] . Conversely, regarding the effect of C3435T on quetiapine, the same study found that the T allele was associated with higher placental transfer of quetiapine. A posterior study performed in healthy volunteers observed a higher AUC in individuals with T/T genotype compared to those with C/T genotype [56] . In contrast, we did not find significant correlation between C3435T and quetiapine pharmacokinetics. This outcome matches with the results of Kim et al. whose study in healthy volunteers found no association between ABCB1 polymorphisms and neither quetiapine plasma concentrations nor its pharmacokinetics [57] .
A possible explanation for these contradictory results could be due to differences in the study designs such as the sample size or the data analysis procedures. Thus, further studies are required to better understand the above findings.
Risperidone. Several studies demonstrated risperidone to be a substrate of P-gp through both in vitro assays and in vivo animal models [48, 58] . It is also proved that risperidone acts as an inhibitor of P-gp and high concentrations of the drug can inhibit its own transport [59] . As risperidone is clearly a P-gp substrate, we expected to see effects of the C3435T polymorphism on its pharmacokinetics. We found several associations of the presence of the T allele with risperidone and 9-OH-risperidone pharmacokinetic parameters. AUC, C max and T 1/2 are lower in carriers of the T allele. According to this trend, we found higher Cl/F levels in T allele carriers, which proved to be statistically significant. Regarding those findings in risperidone, we also observed an association in 9-OHrisperidone whose T allele carriers had lower AUC and T 1/2 and higher Cl/F. According to our knowledge, most studies did not find correlation of C3435T polymorphism with risperidone pharmacokinetics [60, 61] or its clinical outcome [62, 63] . One study found associations between higher plasma concentrations of risperidone and the presence of T allele [62] . Another study observed the opposite effect: lower plasma concentrations of 9-OH-risperidone associated with an ABCB1 haplotype, which included the T allele of C3435T [64] . Further studies with preselected individuals with either homozygous wild-type or homozygous mutated genotypes could be useful to elucidate whether any polymorphisms in ABCB1 show relevant deviations in risperidone disposition.
Aripiprazole. Aripiprazole is a substrate of P-gp [59, 65] . A study conducted in ABCB1-deficient mice showed that there was not a significantly altered plasma drug concentration but strong effects on aripiprazole concentrations in brain tissue [66] . Likewise, Suzuki et al. interrogated the effect of two ABCB1 polymorphisms (C3435T and G2677T/A) on the steady-state plasma concentrations of aripiprazole in 89 patients, finding that ABCB1 genotypes seemed unlikely to have an impact on aripiprazole pharmacokinetics [67] . On the contrary, a recent study analysing the effect of C3435T and G2677T/A SNPs found that individuals with 3435TT/2677TT genotype had significantly lower aripiprazole plasma concentrations [68] . Moreover, we have previously reported the influence of another ABCB1 SNP (C1236T) on the pharmacokinetic parameters of both aripiprazole and its metabolite [43] . In our study, after correction for the impact of CYP2D6 phenotypes, we could observe that T/T carriers presented significantly lower dehydroaripiprazole AUC and C max . As C3435T and C1236T SNPs are in partial linkage disequilibrium (R 2 = 0.52 in IBS) [69] , C3435T T allele is correlated with C1236T T allele. This could explain our results, being C1236T the SNP that causes the association with the pharmacokinetic parameters of aripiprazole and its metabolite.
Genotype influence on pharmacokinetics of antidepressants.
Trazodone. Trazodone induces expression of P-gp in cell culture [70] . Augmented expression could induce higher clearance of antidepressants [71] which may explain why C3435T T allele homozygous showed lower concentrations and higher Cl/F of trazodone. We have previously reported that T/T carriers experienced higher incidence of some adverse drug reactions, possibly due to a lower concentration of trazodone and higher concentration of its active metabolite [37] . Further studies should be performed to elucidate whether P-gp may affect the pharmacokinetics of trazodone and its metabolite.
Sertraline. Sertraline has high affinity for P-gp in vitro [72] . The studies which examine the associations between diverse ABCB1 SNPs and pharmacokinetics of sertraline failed to find any association. Additionally, we have previously found an influence of CYP2C19 and CYP2B6, but not of ABCB1 [38] , on sertraline pharmacokinetics which was also confirmed in this study. However, other polymorphisms in ABCB1, such as rs2032583, rs2235040 and rs9282564, but not C3435T [73, 74] , have earlier been linked with remission and side effects of depressive patients treated with sertraline [73, 75] . It is necessary to clarify whether this or other polymorphisms in ABCB1 can affect sertraline disposition and then have an impact on patients' outcome.
Agomelatine. Based on our knowledge, there is a lack of studies investigating the effect of C3435T polymorphism on the pharmacokinetics of agomelatine. However, C/C genotype has been previously linked to a better response to agomelatine in patients with depressive disorder [76] . In our study, we were not able to demonstrate an effect on pharmacokinetic parameters, possibly due to the high intra-and inter-individual variability [77] and the low sample size, which only allowed us to find 2 individuals carrying the T/T genotype. Further studies in a large cohort of healthy volunteers and patients will possibly allow evaluating the role of ABCB1 in agomelatine disposition.
Citalopram. There is a tight linkage block (R 2 ≥ 0.8) of 9
ABCB1 SNPs in which the presence of the minor alleles has been linked to a better response to substrates of P-gp, like citalopram [23, 75] . On the contrary, another study investigating the effect of C3435T, among other polymorphisms, reflects no association with response or tolerance to pharmacological treatment with citalopram [30] . However, up to date, no study examining the effect of C3435T on the pharmacokinetics of citalopram has been performed. We have found a tendency in T allele carriers to have higher AUC and significantly higher C max in case of C/T genotype which can explain a higher disposition of citalopram and then a better response to treatment. However, the small sample size could be masking a stronger effect.
Recent studies interrogating the effect of the most important pharmacogenes have demonstrated that the majority of variants are very rare and unlikely observed in common approaches [78] . Among them, ABC transporters showed the highest number of variants and the highest very rare (MAF < 0.1%) variants proportion [79] . Approximately 30%-40% of the functional variability can be due to rare variants [79] .
Based on our evidence and the reviewed bibliography previously mentioned, we considered insufficient to analyse C3435T as the only ABCB1 variant with implications in drugs pharmacokinetics. In addition, minimal effects observed in blood can be further noticeable in brain due to the expression of P-gp in the BBB. Indeed, it has been previously stated that differences in concentrations of aripiprazole in serum between wild-type and P-gp K.O. mice were not as significant as the concentrations found in brain [80] . Therefore, further research is a requisite prior to propose a dose adjustment.
Study limitations.
A limitation of our study is that the measurements of drug concentrations were performed in blood, but P-gp activity would be conceivably greater in brain. Moreover, the study design is an important limitation as single-dose administration in healthy individuals prevents us from assessing long-term effectiveness and safety. Pharmacokinetics, pharmacodynamics and tolerability might vary in patients receiving chronic treatment. Additionally, these results must be interpreted with caution given the small sample size for some drugs. Moreover, as the sample size calculation of these studies was not performed for the comparison of genotypes but for evaluation of bioequivalence, the power of the statistical analyses was low. However, a single-dose design in healthy individuals can assess the effect of genetic polymorphisms on antipsychotics and antidepressants without other confounding factors, such as smoking or concomitant treatments. The validity of these results needs to be confirmed in other similar settings with larger sample size and studies in patients receiving chronic treatment.
Conclusions
Numerous studies have pursued to find associations between diverse SNPs in ABCB1 and the pharmacokinetic parameters of certain drugs, arising various and conflicting results [81, 82] . ABCB1 C3435T polymorphism can affect the elimination of some drugs in different ways. In case of risperidone, trazodone and dehydro-aripiprazole, we observed enhanced elimination while it was reduced in olanzapine and citalopram. However, in quetiapine, aripiprazole, sertraline and agomelatine, no changes were detected.
Moreover, the slight differences in drugs concentrations identified in blood need to be confirmed in brain to better relate ABCB1 polymorphism and CNS drug disposition. These results suggest that P-gp could affect CNS drugs disposition, nonetheless, the genetic factor which alters its activity is still unknown. This leads to consider the analysis of ABCB1 haplotypes instead of individual SNPs. As many ABCB1 polymorphisms are in partial linkage disequilibrium, C3435T is likely to be in a similar situation with the responsible SNP that is affecting P-gp activity. This fact can explain why C3435T has diverse effects on different drugs. The authors are grateful to the volunteers and the effort of the staff of the Clinical Trial Unit of Hospital Universitario de la Princesa.
